Investor Presentation - First Six Months of 2021
13
Investor presentation First six months of 2021
CVD presence has been expanded with the Heartseed
collaboration and Prothena ATTR amyloidosis acquisition
Novo Nordisk CVD ambition:
Company
New partnerships and acquisitions to support ambition
Type of agreement
Key asset
Heartseed Inc.
Treatment scope
At least one product
launched between
2024-2028 targeting
atherosclerotic
cardiovascular disease
or heart failure
Exclusive worldwide
collaboration and
license agreement
HS-001
(a stem-cell based
therapy)
Heart failure
Prothena
Corporation plc
Acquisition of
Prothena's ATTR
amyloidosis
programme
PRX004
(an anti-amyloid
immunotherapy)
Expected timing
Heartseed expects
to initiate a phase
1/2 trial in Japan in
H2 2021
ATTR-CM (a rare
heart disease)
Phase 2 expected
to initiate in 2022
followed by a
phase 3 CVOT
Clinical assets:
Ziltivekimab Oral PCSK9i
Other CVD activities
Ongoing major CVOTS:
SELECT
SOUL
FLOW
FOCUS
Note: ATTR-CM Transthyretin Amyloid Cardiomyopathy; CVOT: Cardiovascular Outcome Trial; CVD: Cardiovascular Disease
Novo NordiskⓇView entire presentation